Status:
COMPLETED
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
Lead Sponsor:
AbbVie
Conditions:
Hepatitis C Virus (HCV)
Eligibility:
All Genders
Up to 99 years
Brief Summary
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genoty...
Eligibility Criteria
Inclusion
- Patients with chronic hepatitis C virus infection and administering glecaprevir plus pibrentasvir.
Exclusion
- Patients previously treated with glecaprevir plus pibrentasvir.
Key Trial Info
Start Date :
December 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2020
Estimated Enrollment :
1095 Patients enrolled
Trial Details
Trial ID
NCT03341871
Start Date
December 27 2017
End Date
September 15 2020
Last Update
September 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbvie Japan /ID# 161985
Tokyo, Japan, 108-6302